吡罗昔康治疗急性肌肉骨骼疾病的多中心研究，涉及3011例患者。
Multicenter study of piroxicam in the treatment of acute musculoskeletal diseases involving 3011 patients.
作者信息
Filho J L
出版信息
Eur J Rheumatol Inflamm. 1983;6(1):119-25.
An open non-comparative study was conducted to assess the efficacy and tolerability of piroxicam in patients with acute musculoskeletal disease. A total of 3011 patients of both sexes, aged between 18 and 70, were treated with piroxicam: 4 capsules (40 mg) after dinner, on the first two days and two capsules (20 mg) on the following days. Patients were evaluated for a maximum period of 14 days. Assessment of efficacy was made including local pain and limitation of mobility. The patients' self-assessment of pain was also analyzed. A clear improvement in each of the parameters analyzed was found by the third day of treatment. The general self-assessment of efficacy by the patients presented excellent and good results in 97.5%; very similar to the final assessment of efficacy made by the doctors, 91.1%. Adverse reactions were found in 368 patients (12.22%).
开展了一项开放性非对照研究，以评估吡罗昔康对急性肌肉骨骼疾病患者的疗效和耐受性。共有3011名年龄在18至70岁之间的男女患者接受了吡罗昔康治疗：前两天晚餐后服用4粒胶囊（40毫克），之后每天服用2粒胶囊（20毫克）。对患者进行了最长14天的评估。评估疗效时包括局部疼痛和活动受限情况。还分析了患者对疼痛的自我评估。在治疗的第三天，所分析的各项参数均有明显改善。患者对疗效的总体自我评估中，97.5%的结果为优或良；这与医生对疗效的最终评估非常相似，后者为91.1%。368名患者（12.22%）出现了不良反应。
Zotero 插件